R289, a dual IRAK1/4 inhibitor, has received fast track status from the FDA for treating transfusion-dependent lower-risk MDS ...

On immune cells, Toll-like receptors are capable of detecting infections just like a sniffer dog, using special sensors known as Toll-like receptors, or TLRs for short. But what signals activate ...

"For instance, it's quite possible that different molecules stimulate the same TLR but trigger different ... when the receptor switches on a certain signaling pathway in which these molecules ...

“For instance, it’s quite possible that different molecules stimulate the same TLR but trigger different responses ... when the receptor switches on a certain signaling pathway in which these ...

Immune cells are capable of detecting infections just like a sniffer dog, using special sensors known as Toll-like receptors, or TLRs for short. But what signals activate TLRs, and what is the ...

“For instance, it’s quite possible that different molecules stimulate the same TLR but trigger different ... when the receptor switches on a certain signaling pathway in which these molecules ...

"For instance, it's quite possible that different molecules stimulate the same TLR but trigger different ... when the receptor switches on a certain signaling pathway in which these molecules ...

Following a phase 1b trial, the potent and selective dual inhibitor of IRAK1 and IRAK4 received fast track designation for the treatment of patients with lower-risk myelodysplastic syndrome.

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast ...